title: Live oral Salmonella enterica serovar Typhi vaccines Ty21a and CVD 909 induce opsonophagocytic functional antibodies in humans that cross-react with S. Paratyphi A and S. Paratyphi B.
abstract: Live oral Salmonella enterica serovar Typhi vaccine Ty21a induces specific antibodies that cross-react against Salmonella enterica serovar Paratyphi A and Salmonella enterica serovar Paratyphi B, although their functional role in clearance remains unknown. We utilized an in vitro assay with THP-1 macrophages to compare the phagocytosis and survival of Salmonella opsonized with heat-inactivated human sera obtained before and after vaccination with Ty21a or a live oral S. Typhi vaccine, CVD 909. Opsonization with postvaccination sera predominantly increased the phagocytosis of S. Typhi relative to the corresponding prevaccination sera, and increases were also observed with S. Paratyphi A and S. Paratyphi B, albeit of lower magnitudes. Relative to prevaccination sera, opsonization with the postvaccination sera reduced the survival inside macrophages of S. Typhi but not of S. Paratyphi A or S. Paratyphi B. Higher anti-S. Typhi O antigen (lipopolysaccharide [LPS]) IgG, but not IgA, antibody titers correlated significantly with postvaccination increases in opsonophagocytosis. No differences were observed between immunization with four doses of Ty21a or one dose of CVD 909. Ty21a and CVD 909 induced cross-reactive functional antibodies, predominantly against S. Typhi. IgG anti-LPS antibodies may be important in phagocytic clearance of these organisms. Therefore, measurement of functional antibodies might be important in assessing the immunogenicity of a new generation of typhoid and paratyphoid A vaccines. (The CVD 909 study has been registered at ClinicalTrials.gov under registration no. NCT00326443.).
authors.affiliation: Center for Vaccine Development, Departments of Pediatrics and Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
authors.forename: Rezwanul
authors.initials: R
authors.lastname: Wahid
authors.forename: Shah J
authors.initials: SJ
authors.lastname: Zafar
authors.forename: Monica A
authors.initials: MA
authors.lastname: McArthur
authors.forename: Marcela F
authors.initials: MF
authors.lastname: Pasetti
authors.forename: Myron M
authors.initials: MM
authors.lastname: Levine
authors.forename: Marcelo B
authors.initials: MB
authors.lastname: Sztein
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood* / Q000276:immunology; D002460:Cell Line; D002470:Cell Survival; D003429:Cross Reactions; D005260:Female; D006801:Humans; D008264:Macrophages / Q000276:immunology; D008297:Male; D009895:Opsonin Proteins / Q000097:blood* / Q000276:immunology; D010587:Phagocytosis; D012482:Salmonella paratyphi A / Q000276:immunology*; D012484:Salmonella paratyphi B / Q000276:immunology*; D012485:Salmonella typhi / Q000276:immunology*; D014436:Typhoid-Paratyphoid Vaccines / Q000008:administration & dosage / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology; D055815:Young Adult
chemical_list: D000907:Antibodies, Bacterial; D009895:Opsonin Proteins; D014436:Typhoid-Paratyphoid Vaccines; D014613:Vaccines, Attenuated